Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Alliance Pharma to bank £2.9mln from the sale of Chinese rights to pregnancy supplement

A £1.5mln shareholder loan will also be repaid, the company told investors

Alliance Pharma plc (LON:APH) is selling the Chinese rights to Forceval, a micro-nutrient supplement used in pregnancy, for £2.9mln.

It doing so via the disposal of its 60% stake in a company called Unigreg Limited to Pacific Glory Development.

As well as the sale proceeds, which will be staggered over two payments, with the final £500,000 instalment expected within the next year, Alliance will be repaid a £1.5mln shareholder loan.

Bank debt reduced

The proceeds of the deal will be used to reduce bank debt.

Alliance said it remains committed to China, having set up an affiliate in Shanghai to sell a range child nutraceutical products in the People’s Republic. It also has a distributor in the same city for its Kelo-cote product for scarring.

Alliance also confirmed it will continue to market the Forceval brand in the UK.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK